Open Access<p>Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective</p>
Author(s) -
Melanie Schroeder,
Nicole Benjamin,
Laura Atienza,
Chandroday Biswas,
Antonio Jiménez Martín,
John Whalen,
José L. Alonso,
Juan Antonio Riesco,
Juan José Soler-Cataluña,
A. Huerta,
Afisi S Ismaila
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s240556
Subject(s) - medicine , copd , fluticasone propionate , exacerbation , population , incremental cost effectiveness ratio , salmeterol , cost effectiveness , budesonide , quality adjusted life year , physical therapy , asthma , environmental health , risk analysis (engineering)
To evaluate the cost-effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) vs twice-daily budesonide/formoterol (BUD/FOR) in patients with symptomatic chronic obstructive pulmonary disease (COPD) at risk of exacerbations, from the Spanish National Healthcare System perspective.